dc.contributor.author | Hancer, Veysel Sabri | |
dc.contributor.author | Akturk, Faruk | |
dc.contributor.author | Kucukkaya, Reyhan | |
dc.date.accessioned | 2021-03-03T16:26:48Z | |
dc.date.available | 2021-03-03T16:26:48Z | |
dc.date.issued | 2010 | |
dc.identifier.citation | Akturk F., Hancer V. S. , Kucukkaya R., "Cytotoxic T lymphocyte antigen-4 (CTLA-4) A49G polymorphism and autoimmune blood diseases", TURKISH JOURNAL OF HEMATOLOGY, cilt.27, sa.2, ss.78-81, 2010 | |
dc.identifier.issn | 1300-7777 | |
dc.identifier.other | vv_1032021 | |
dc.identifier.other | av_444855b6-f82d-42ef-9f72-726c518df442 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12627/49590 | |
dc.identifier.uri | https://doi.org/10.5152/tjh.2010.04 | |
dc.description.abstract | Objective: The cytotoxic T lymphocyte associated antigen-4 (CTLA-4) is expressed on T lymphocytes, and inhibits the T-cell responses. In animal models, it has been shown that complete CTLA-4 deficiency was lethal due to massive infiltration of tissues by polyclonally proliferating lymphocytes. CTLA-4 A49G polymorphism, which has been suggested to reduce the inhibitory function of the CTLA-4 molecule, was found to be associated with various autoimmune diseases in recent studies. | |
dc.language.iso | eng | |
dc.subject | Sağlık Bilimleri | |
dc.subject | Hematoloji | |
dc.subject | Dahili Tıp Bilimleri | |
dc.subject | Tıp | |
dc.subject | Klinik Tıp (MED) | |
dc.subject | Klinik Tıp | |
dc.subject | HEMATOLOJİ | |
dc.subject | İç Hastalıkları | |
dc.title | Cytotoxic T lymphocyte antigen-4 (CTLA-4) A49G polymorphism and autoimmune blood diseases | |
dc.type | Makale | |
dc.relation.journal | TURKISH JOURNAL OF HEMATOLOGY | |
dc.contributor.department | İstanbul Üniversitesi , , | |
dc.identifier.volume | 27 | |
dc.identifier.issue | 2 | |
dc.identifier.startpage | 78 | |
dc.identifier.endpage | 81 | |
dc.contributor.firstauthorID | 196414 | |